Tirzepatide 15mg

Buy Tirzepatide 30mg

Tirzepatide is a synthetic 39-amino-acid peptide and a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly and Company. Unlike selective GLP-1 receptor agonists, tirzepatide activates both incretin pathways within a single molecule, making it an important subject of research in incretin signaling, glucose metabolism, energy regulation, and metabolic biology.

The peptide was designed with structural modifications that extend its circulating half-life, allowing researchers to investigate sustained GIP and GLP-1 receptor activation. Clinical research has produced substantial data on its pharmacological profile. In the SURPASS-2 Phase 3 trial, involving 1,879 participants, tirzepatide produced greater reductions in HbA1c than once-weekly semaglutide at the doses studied.

Tirzepatide has also been extensively investigated in obesity research. The SURMOUNT-1 Phase 3 trial included 2,539 participants and evaluated 5 mg, 10 mg, and 15 mg doses over 72 weeks. The study reported substantial, sustained changes in body weight and improvements across prespecified cardiometabolic measures.

More recent research has extended the SURMOUNT-1 dataset to 176 weeks, examining longer-term outcomes in participants with obesity and prediabetes. The study investigated both sustained weight changes and progression to type 2 diabetes, providing additional data on the long-term effects of tirzepatide exposure.

For laboratory research, tirzepatide provides a well-characterized model for studying dual incretin receptor signaling, peptide pharmacology, metabolic pathways, and GIP/GLP-1 receptor biology.

Research Use Only: This product, and all other prodcuts available at Sequora Peptides,  are intended exclusively for laboratory research. It is not intended for human or veterinary use, diagnosis, treatment, or prevention of disease.

Selected Research Papers

1. Frías JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine.
2. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038.
3. Tirzepatide for Obesity Treatment and Diabetes Prevention (2024). New England Journal of Medicine. The extended SURMOUNT-1 analysis examined 176-week outcomes in participants with obesity and prediabetes.